Ovation’s Sabril Gets Advisory Committee Nod; Risk Strategy To Address Vision Loss Needed
This article was originally published in The Pink Sheet Daily
Executive Summary
The recommendation is contingent upon development of a REMS to detect the risk of visual field defects.
You may also be interested in...
Sabril Benefits In Infantile Spasms Outweigh Risk Of Vision Loss, Advisory Committee Says
Ovation anti-epileptic gains second unanimous approval recommendation from FDA committee; limited clinical data on vision loss means post-market studies are likely.
Sabril Benefits In Infantile Spasms Outweigh Risk Of Vision Loss, Advisory Committee Says
Ovation anti-epileptic gains second unanimous approval recommendation from FDA committee; limited clinical data on vision loss means post-market studies are likely.
Ovation’s Sabril Visual Defect Is Topic Of FDA Meeting; Is End To Longest Review In Sight?
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will evaluate vigabatrin for two epilepsy indications at a meeting rescheduled for Jan. 7-8.